Talking Biotech Podcast

After a three month hiatus the Talking Biotech Podcast is back. Today's episode is a visit with Colarbra CEO Aoi Senju about his view for the podcast, followed by synopsis of three major news stories that broke since the last Talking Biotech Podcast. The new format includes a video component, and I'll be speaking with panels and also discussing recent news stories. It is an exciting opportunity to capture a new audience, expand listenership, and provide new levels of programming to the popular format.  Thank you for your patience and I hope you enjoy the new episodes. Kevin

After 8.5 years of weekly podcasts I'm going to take a 5 week break and plan new episodes for 2024.  I'm going through a medical glitch that has me unable to do my normal work. On top of this we're going to switch to an audio plus video format to find a wider audience. So check back in 2024 for the next episode. Have a great rest of 2023, thank you for listening, and looking forward to better times. 

Even under the best conditions, crops need our assistance to survive the numerous threats that limit production. Classically, synthetic and natural compounds have been used to control insects, fungi and weeds, sometimes with negative collateral effects or fostering resistance of genetically tolerant genotypes. Todd Hauser from Trillium Ag describes his company's novel RNAi approach.  RNAi can be used to target specific insect species, and his company's design and particle-based technology appears to offer safety, effectiveness, and specificity. We discuss the use of RNAi and how it may be a key point of crop protection strategies, along with its inherent challenges.  

There is tremendous variation in the plant kingdom, as plants have adapted to many ecological niches with discrete challenges. Part of adaptation is production of novel secondary metabolites, compounds not required for central metabolism that serve a role in the plant, such as defense or attraction of pollinators. The rainforest is replete with unusual plants and their resident metabolites. Indigenous peoples have identified therapeutic qualities of specific plants. How can this knowledge be transferred to aid those suffering beyond the rainforest? Lisa Conte is the CEO, President and Founder of Jaguar Health, a subsidiary of Napo Pharmaceuticals.  We discuss process of working with indigenous peoples to learn from their findings, then test and validate them in ways to identify novel mechanisms of action for use in modern medicine. 

Gene editing is a powerful and specific technique that allows customized changes to DNA. Because there are no additional sequences transferred, and alternations match what could happen naturally over time, the technology is considered less invasive and less prone to regulatory oversight. That's true in the USA, Canada, China and other nations. However, the European Court of Justice determined that these techniques should be regulated in a manner identical to transgenics, where the EU has not approved such innovations in over two decades. EU scientists see how the EU is falling behind and after long may never catch up. The rejection of technology leads to a tremendous economic loss. Dr. Emma Kovak of the Breakthrough Institute discusses the current regulations, the proposed changes, and the dynamics of opposition to a good technology that could have profoundly positive impacts for people and the planet. 

Information has been weaponized, and the ability to create false information to achieve an ideological goal has never been more easy. Political polarization, science denial, and a shining, effective conduit of dissemination (the internet) allows anyone with an agenda to recruit the like minded, and produce compelling media to reinforce bankrupt ideas. Where did information warfare originate, what are its effects, and how do we fix it?  This week's podcast discusses the book, On Disinformation: How to Fight for Truth and Protect Democracy with author Dr. Lee McIntyre. The book presents a chilling description of who creates disinformation, how subscribes to it, and its long term effect on free society. Fortunately, solutions are proposed that can help curb the penetration of disinformation, particularly as it becomes more effective through artificial intelligence. 

While DNA captures most of the fanfare, proteins are the catalytic and structural superstars of the cell. However, they can also become problematic. Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that's added that signals that a protein should be moved to the biochemical garbage can.  Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction. The goal of this line of therapeutics is to target a suite of proteins that need to be degraded for normal health and development. Their pipeline contains multiple clinical and pre-clinical trials, and the approach is an exciting complement to other drug discovery methods. 

Recombinant DNA technologies once confined to the laboratory are now available to just about anyone. Is this a good thing or an extreme risk? David Ishee is self-described biohacker, dog breeder and mad scientist, and merges these passions in cutting edge DIY projects and educational tools. We discuss the opportunities and risks in DIY molecular biology, biohacking and democratization of modern genetic plant, animal and microbial genetic tools.  

We're surrounded by microbes, many that are the basis of disease. Others have evolved resistance to our best antibiotics. Others may be weaponized for bioterrorism. Because microbial threats can evolve rapidly and grow quickly, early detection of a microbial threat is essential. Dr. Brad Perkins of Karius describes the threats of microbes, his company's novel approach to fast and easy test that can detect evidence of thousands of putative pathogens in a small blood sample, essentially overnight. We discuss the technology and its applications. The technology stands to be an important tool to ensure a lower-risk pathogen environment in medical facilities, as well as detect putative pathogens before they become major problems for a patient or broader population. 

The Pawpaw (Asimina triloba) is the largest native North American fruit, and grows wild throughout most temperate forests of the eastern United States and Canada, from southern Ontario to the Florida border. Several breeding efforts have sought to improve this tree crop, seeking mostly to improve fruit quality, especially post-harvest. The fruits feature a tropical flavor, a flesh that has been described as everything from marshmallow to banana, in a custard-like texture. Despite its flavorful appeal, few have experienced this fruit, mainly because of its perishable nature, and the fact that wildlife appreciate the fruit before humans ever get to it. However, a new initiative called Project Pawpaw seeks to improve the species for fruit production. Director Adam D'Angelo speaks about fundraising efforts to grow breeding populations, and utilize modern approaches to hasten development of improved pawpaws. Project Pawpaw websiteFollow on Instagram

In today's episode I cover two topics with Cameron English, science journalist and podcast host.  We discuss the current status of citrus greening disease in the USA, a disease that has ravaged the Florida juice industry. We also discuss the copious disinformation around seed oils, which many internet sources claim to be dangerous. 

The connection between tobacco smoke, cancer and heart disease has been well established since the 1800's, with irrefutable medical evidence presented since the 1950s. There is no question that smoking has significant public health impacts. The effects of second hand smoke were examined in various studies and  also claimed negative effects. But these reports has some significant limitations, and larger studies later showed no significant risk.  One of the authors, cancer epidemiologist Dr. Geoffrey Kabat, recounts the publication, the fallout, the lack of defense from the scientific community, and later independent reports that would reinforce their findings of no association with lung cancer and heart disease. While predating social media, the findings that did not fit a public health narrative where harshly criticized, using arguments that failed to address the evidence. This example is a precursor to understanding the modern-day discussions about issues like vaccination, COVID19, glyphosate, and other topics where the evidence is strong, but public opinion often fails to accept it. Dr. Kabat's accompanying article on Quillette. 

This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a novel non-profit model. The second half address two rare genetic eye diseases and the approaches being designed to address them. Dr. Ashley Winslow, CEO/CSO of Odylia, describes how a non-profit is well suited to address these rare diseases, using strategies that leverage capacities in rare disease patient communities coupled to their expertise in drug discovery.  

The more information you know about your genetics the better, right?  This is the idea behind companies like 23andMe, which offer platforms to understand your potential genetic predisposition toward a specific disease. The concept thrives on massive collection of public genetic data, coupled to extensive questionnaires that en masse, generate statistical associations between different genetic variants and various disorders, diseases, behaviors or drug sensitivities. These powerful tools are shaping our understanding of genes and genetic variants that contribute to our physiology, metabolism and psychology, and even aiding in drug discovery. Dr. Joyce Tung, Vice President of Research at 23andMe describes the technology, the evolution of the business, racial disparities, and what the future looks like for public genetic services. 

DNA has been an invaluable tool to make certain matches between a suspect and a crime. Since its early use in the 1980s, we have seen an explosion in DNA sequence availability, allowing forensic scientists to identify hypervariable regions of the genome that can assist in confirming a person's identity. However, there are many ethical issues surrounding its implementation, such as use of public and private databases (like 23 and Me) to identify a suspect. The discussion covers a breadth of forensic applications with Brian Hoey, Director of the Missouri State Police Crime Lab. 

If you've ever publicly communicated enthusiasm for a new product or technology, you inevitably have been accused to being a shill for the company that produced it. It is a normal part of human psychology to assume there is an undisclosed motivation for someone's excitement, and it is based on legitimate concerns about how conflicts of interest can shape one's perceptions of associated science. We discuss the topic with Dr. Chris MacDonald from Toronto Metropolitan University.  

Many consumer products contain chemistries that originate from an unsustainable source. Dr. Chance Elliott VP of R&D at Amyris describes how his company is using synthetic biology to engineer yeast to produce these same compounds from sustainable substrates. We also discuss the current business climate, how companies change with new technology, as well as how to prepare for a future for jobs in this rapidly evolving space. 

The company Color has taken innovative approaches to varied aspects of public health.  From at-home kits that can assess cancer risk, to efforts to curb COVID19, to finding attractive ways to make health care more accessible, Color has launched an array of programs that seek to improve public health.  Dr. Alicia Zhou is the Chief Science Officer of Color.  We discuss Color's efforts in cancer and disease detection, it's inroads into personalized, precision medicine, and a look at how technology may enable improved access to quality health care.  We also discuss careers in this evolving space, and how the business is adapting to a changing health care  delivery landscape in positive ways that benefit the patient and the system as a whole. 

This is one hot tech discussion!  Protein therapeutics have great potential, but significant limitations to their utility. Dr. Dan Mandrell of Gro Biosciences explains how they are using a non-standard library of amino acids to increase protein presentation. Along with glycosylation and other modifications, the proteins are more therapeutically active. 

While many global genomics analyzes gene variants or RNA expression products, the levels of proteins are usually the most informative.  At the same time, quantifying proteins is relatively difficult, especially when trying to obtain a snapshot of the proteome from a single cell or tissue. Dr. Parag Mallick of Stanford University and Nautilus Biotechnology describes the utility of high-throughput proteomics, and how the technology incorporates a novel detection method and machine learning to quantify large suites of proteins. The applications are almost endless and present great opportunities to understand how accumulation of specific proteins relates to biological function or disease states. 

Many diseases or disorders originate with a loss of cellular function.  Cell death or damage is at the root of many problems associated with aging or injury. But what if the cells lost could simply be replaced to restore function?  Brian Culley, CEO of Lineage Cell Therapeutics, discusses how his company has identified ways to generate specific cell types that can functionally replace lost cells in various contexts, restoring function. We discus applications in macular degeneration, hearing loss, and spinal cord injury, with potential applications in Type 1 diabetes, Parkinson's disease, and many future applications. 

Dr. Mike Tarselli, CSO of Tetra Science and Kevin Folta have a conversation about careers in biotech, where the discipline is going, along with observations about what makes someone successful in the field. We share many personal experiences as well as projections, and lessons we learned along the way.  This is a great episode if you are considering a career in biotechnology. 

What can be learned about biology from massive datasets, and can that information unveil opportunities for new therapeutics?  This is the approach by Turbine.  Today's podcast discusses Turbine's approach with Dr. Dan Veres, CSO and Co-Founder of the company. He describes how data sets from multi-omics analysis are merged and analyzed to identify potential drug targets. and in silico information informs wet lab tests. The outcome is new therapeutics to treat recalcitrant disease.  Webiste: www.turbine.ai

The COVID19 pandemic was a challenge in public health, but became much worse through politicization of science and a thriving misinformation network. Over a short time, a cadre of personalities emerged in a willing media that made claims contrary to public health guidance, stoking suspicion and eroding trust in the messaging from public health experts. Dr. Jonathan Howard's book, "We Want Them Infected" is a collection of social and traditional media comments by contrarian physicians and media personalities that frame the dissent against public health guidance. Dr. Howard uses their own words to illustrate how a handful of personalities hijacked a health crisis to personally benefit, while providing false and dangerous information that clouded pandemic response, and eroded trust in vaccinations and other aspects of public health. Buy "We Want them Infected" at Redhawk PublicationsOr on Amazon   

Robert F. Kennedy Jr. is recognized for his bad science around critical issues like vaccination and agricultural chemistry.  Recently he enjoyed a long-form, virtually uncontested platform on the Joe Rogan Experience where he rattled misinformation after falsehood about everything from vaccination to disease to glyphosate to cell phones. Because Rogan has a massive audience, this information is particularly dangerous. Here I refute, point-by-point, the false assertions made by Kennedy, and clearly show that he is simply a motivated disinformation hustler, and his false information must be corrected. In this podcast I refute his points with evidence, and show why he should not be trusted for information about medicine or agriculture. 

The avocado is a wonderful fruit that is gaining in popularity, full of healthful oils and other nutrients.  However, consumers consistently note the obvious drawback of the short life of fresh avocados, especially when used in recipes, like guacamole. Oxidative browning occurs within minutes, and causes food waste and supply chain loss. Green Venus is a technology company that has used site-specific nucleases to edit the genome of avocado. Dr. Jeff Touchman discusses the challenges and opportunities, regulatory hurdles, and specifics of the edits, as well as the potential future of a genetically engineered avocado.  

The 400th episode also represents the first episode of the 9th year-- an amazing run for a tiny, self-produced podcast.  Where did it come from?  In this episode I talk about the genesis of the Talking Biotech podcast, from the Vern Blazek Science Power Hour, to an arm twisting by Joe Rogan, to being banned from podcasting by my university-- this is a behind-the-scenes history of this effort. I also recognize the guests that are no longer with us, yet remain a vital part of this archive. 

Vaccination is a cornerstone of animal health, and is critically important in animal agricultural operations. A number of devastating livestock diseases are prevented with vaccination, yet vaccines have not been developed for some of the most devastating diseases for several reasons. Long before the COVID pandemic and its slate of next-gen vaccine strategies, Harris Vaccines was using rapidly adaptable RNA-based vaccine technologies. The current suite of RNA-based vaccines have been used successfully in swine for years, with many others in development. Today's discussion is with Joel Harris, CEO of Genvax.  We discuss the technology and its applications. www.genvax.com@genvax @JoelTHarris

Sam Kean is a prolific author that has a unique talent for sharing the stories of science.  Trained in physics, Kean's work describes seminal events in science using a deeply researched narrative style that transforms textbook information into better-than-fiction stories of discovery. In today's episode guest co-host Gracelyn Byrd joins the podcast to discuss the state of science communication, how we can do better as scientists and science institutions, and discuss how today's events may be reflected in time. Sam Kean on Twitter:  @Sam_Kean

The human brain is complex, but over the years massive data have been gathered regarding the relationship between structure and function.  From functional MRI to many other techniques, researchers slowly are resolving the relationship between brain anatomy and how it actually works. Dr. Stephan Doyen of Omniscient Neurotechnology have designed tools to parse massive collections of data relating brain structure to function, and now provide a set of tools to guide surgeons, as well as potentially serve as predictive tools in addressing challenging neurological disorders. Website: https://www.o8t.com/

The kidney is one of the organs necessary to filter blood, composed of tiny functional units that separate waste products from molecules the body should retain. Chronic kidney disease is a significant international problem, with up to 10% of the population requiring treatment, and extreme cases requiring dialysis and/or transplantation with significant personal and public health costs. In today's episode we speak with Dr. Andrew King, Chief Scientific Officer of Chinook Therapeutics.  We discuss rare diseases of the kidney, such as disorders that lead to nephropathy, proteinuria, and oxalic acid deposition, along with how the next generation of drugs work to target these issues. www.chinooktx.com

Plant biologists use a set of tools to modulate gene expression. The well-established set of molecular switches are rather crude, with limited control of spatial or temporal expression.  Dr. James Lloyd discusses the newest tools in synthetic circuits, molecules that can tailor a response with a given input. These new tools add needed nuance to the regulation of gene expression and stand to revise how we control specific genes in the lab and field. 

Scientists are encouraged to step into the public conversation around controversial work, especially when that work seems to deliberately misinform, and can negatively affect public health.  A series of authors have used to COVID pandemic to use the peer-reviewed literature to push claims that are poorly supported by legitimate evidence. These papers find favorable review from poor-quality reviewers, leading to eventual publication, and earning the patina of legitimacy, despite the poor quality of the work. Dr. Lonni Besançon and an expert team responded to a paper online that presented no original research-- just a hypothesis that is supported by cherry picked data to support a conclusion. The team wrote a response to the journal, which was peer reviewed prior to publication, yet the journal still declined to print it. This conversation shows that the claims of silencing and censorship are not stopping bad information-- but we can identify cases where efforts to correct the information are rejected. The paper by Barrière et al. https://link.springer.com/article/10.1007/s12015-022-10465-2

The companies on the front edge of pharmaceutical development have identified the value of massive data sets in the future of drug design. Ironically, personalization of therapies will be improved tremendously through examination of massive data sets. Dr. Michael Zaizac from Novartis of Europe discusses how his company has they have integrated artificial intelligence and analysis of patient data sets for new discoveries in patient care. 

As we age, the brain undergoes changes that lead to various disorders that affect physical ability and mental acuity. There are many processes at play, ranging from alterations in the extracellular environment, to accumulation of deleterious proteins, to a breakdown in connections between neurons. Can these processes be reversed?  Dr. Jean Herbert from the Albert Einstein School of Medicine has led efforts to reconstitute brain function through use of stem cells. Current steps in animal models may one day contribute to human therapies. 

The COVID pandemic accelerated development of a new class of vaccines. This class, called mRNA vaccines, allows ease in manufacture, rapid response to disease or disease variants, and many other benefits.  But just like any technology, an industry has arisen to stand in its way, promoting false information that painfully mischaracterizes what these new veterinary tools truly are. A cadre of internet personalities now capitalizes off of the manufactured fear that can help farmers, consumers and the environment-- as well as fortify animal welfare.  University of California scientists Dr. Alison Van Eenennaam and Dr. Terry Lehenbauer discuss what the mRNA vaccines are, and how efforts to oppose them defy science, especially when codified into law by clueless politicians. 

In a rapidly changing technology environment, how do established businesses tackle smart growth and continue transformative change?  In this special edition of Talking Biotech Podcast we examine the business climate of Regeneron, and how growth in the era of genomics and massive data sets from human health changed the process of drug discovery, but also changed how the company would respond to new opportunities and challenges. Dr. Jeffery Reid, Chief Data Officer, explains where the company was, and how it has changed with the rocketing pace of data acquisition and integration. 

In this episode Dr. Kevin Folta shares a spontaneous conversation with Dr. Liza Dunn. Dr. Dunn is an emergency medicine physician with a specialty in medical toxicology, now working as the Medical Affair Lead at Bayer CropScience.  The discussion covers the current scientific environment in social media, and emphasizes the need for scientists to be engaging. Topics from communication about vaccines to genetic engineering are covered. Follow Dr. Dunn at @DrLizaMD

The potato is a world food staple, yet it is constantly threated by fungal and viral pathogens in all of its growing regions. Farmers combat these problems with chemistry, which cuts farmers profits and has potential consequences for applicators and the environment. Dr. David Douches from Michigan State University discusses the USAID project that installed a cassette of disease resistance genes from wild potato species in the cultivated potato. The result is a potato that can survive better in the Developing World, helping to ensure food security. 

Whereas we used to be challenged with finding information, today we are flooded with information, and our job has switched to vetting it's merits. Three students from the University of Florida spoke to me about their efforts in a national competition to study the origins of false information and communicate how to identify good information to the public. Tammy, Heather and Courtney were amazing guests that discussed their mission, along with a suite of online resources to help guide the public to quality information. 

Mental illnesses such as anxiety and depression are being diagnosed with increasing frequency. At the same time, treatment is frequently dependent on legacy drugs that oftentimes to do not work well, have drug interactions, or can lead to addiction or dependence. New therapies are also available, yet they they are systemic and can also have drug interactions and unfavorable side effects. New therapies are needed, especially those with more direct delivery to the relevant regions of the brain. Shawn Singh, CEO of VistaGen, describes their new drug candidates that target depression and anxiety. The novel compounds are delivered as nasal sprays, providing direct interaction with neurological pathways in the olfactory bulb that connect directly to the regions of the brain that affect mood and anxiety. These candidate therapeutics are less likely to drive side effects due to the low levels delivered and their direct interaction with the brain.   VistaGenwww.vistagen.com www.twitter.com/VistaGen www.facebook.com/VistaGen  

Lipid nanoparticles have been around for decades, but they took a spotlight in the delivery of the COVID19 mRNA-based vaccines. This chemical cage can fuse with cell membranes and deliver a specific payload to a cell. While the delivery to specific cells is routine, are there ways to improve the system to have more specific therapeutic benefit. Dr. John Lewis of Entos discusses lipid nanoparticle chemistry and new formulations that exhibit enhanced capacity to target specific locations and deliver payloads more effectively. We also discuss the current therapies that may benefit from the new technologies. 

There are many rare diseases that originate with a single letter change in DNA, and they can cause tremendous physical and financial hardship for families affected. Viral-based gene therapies have been a promise for decades, and modern technology is now bringing these concepts to fruition. Dr. Gaurav Shah, CEO of Rocket Pharma, describes the power of the current gene therapy approaches, along with the pipeline of potential therapeutics that could represent cures for rare disease. 

This week's podcast has two parts.  Dr. Leen Kawas , Managing General Partner at Propel Biopartners, speaks about how biotech startups can benefit from skilled oversight and capital provided from experts that understand the business/science ecosystem. In the second part we discuss the latest therapies for Alzheimer's Disease, and how trials and regulation can't follow traditional trajectories. Alzheimer's has variation in etiology, patients start treatments after a diagnosis which may be years after the disease is well established, and progression is dependent on many genetic factors. All of these variables make any assessments problematic. At the same time several new antibody-based therapies show promise. 

As the amount of plant genomic DNA sequence increases, scientists have detected DNA sequence information that simply does not conveniently fit into genome assemblies, and clearly appears to be from somewhere else. Dr. Lara Pereira from the University of Sheffield explains the surprising frequency of lateral gene transfer between grass species. The mechanism of crossing the species barrier is discussed, along with the frequency of horizontal transfer. We discuss the ramifications of unregulated integration of DNA into plant genomes and the perception of transgenic plants in the EU and other locations where crop genetic engineering is not viewed favorably. The results also suggest additional care when monitoring gene escape in transgenic grasses like maize.  Follow Dr. Pereira on Twitter at @LarrLarrr

Salmon are outstanding table fare, featuring flavor and nutrition. The AquaAdvantage salmon is a genetically engineered salmon that is resistant to changes in growth due to seasonal fluctuation or the stresses encountered in traditional ocean-net salmon farms. Despite the advantages, the salmon has been caught in deregulation for many years, limiting consumer access. Silvia Wulf of AquaAdvantage talks about the current status of availability, the technology, the criticisms and the future of the AquaAdvantage salmon. 

The mythical Fountain of Youth may be an actual component of our physiology. Aging is not simply the body breaking down against the calendar, it is a coordinated series of molecular/biochemical changes that occur with time. There is an active hypothesis that later-life medical issues are not just happening as we age, but are actually caused by aging, meaning there are potential drug targets that may slow the process. BioAge performed -omics level analysis on populations of aging individuals, revealing patterns of proteins and metabolites that may be causal components of the aging process. New therapeutics seek to target aspects of human senescence, potentially delaying the onset of late-life disease. Dr. Eric Morgen of BioAge describes how his company has used a novel approach to identify new compounds that may play eventual roles in slowing the aging process. 

What are the risks associated with being able to create custom DNA?  Today's podcast discusses the potential weaponization of synthesized nucleic acid sequences. Dr. Kevin Esvelt discusses synthetic DNA and synthetic viruses, along with the possibility that they may drive the next pandemics or become the basis for future biological weapons. The dark realities are discussed, along with surveillance and mitigation strategies, as well as the broken social trust that could fuel a human-made pandemic. 

If a genetic disorder can be detected in the developing fetus, it provides families and physicians vital information that can guide important decisions. From family planning to medical intervention, new molecular techniques are being employed to detect potential anomalies as early as 10 weeks after conception. The modern genetic counselor is an expert at communicating the results of these tests, building trust to advise decisions that benefit the parents and the child.  

While there are many views on Brexit, one certain benefit is the UK's self-governing role in scientific regulatory affairs. The EU's position on genetic engineering has perplexed its scientists, as they create solutions for EU farmers that may never be implemented. Now out from the EU's onerous non-scientific regulatory oversight, the UK may choose to deregulate gene editing. Cameron English talks about the proposed regulatory changes and how they may benefit the UK's farmers and scientists.  You can read his report here:  https://iea.org.uk/publications/harvest-time-why-the-uk-should-unleash-the-power-of-gene-editing/

The American chestnut was a dominant tree in many forests in the eastern United States. In the late 1800's an imported fungus spread rapidly throughout the range, destroying most of the trees in a matter of decades. Scientists at the State University of New York have engineered trees to host a gene from wheat that disarms the fungal invader, breaking the production of an acid required for infection. This strategy allows the tree and the fungus to live together without infection. Erik Carlson discusses the problem, the project, the push back and the current deregulation efforts to release the tree in the interest of repatriating its native range.  Read the release docket and provide your comments here -- https://www.regulations.gov/document/APHIS-2020-0030-8291/comment